- Home
- PBBK vs NXTC Comparison
PBBK vs NXTC Comparison
Compare PBBK & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBBK
- NXTC
- Stock Information
- Founded
- PBBK 1919
- NXTC 2015
- Country
- PBBK United States
- NXTC United States
- Employees
- PBBK N/A
- NXTC N/A
- Industry
- PBBK Banks
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PBBK Finance
- NXTC Health Care
- Exchange
- PBBK Nasdaq
- NXTC Nasdaq
- Market Cap
- PBBK 35.9M
- NXTC 40.3M
- IPO Year
- PBBK N/A
- NXTC 2019
- Fundamental
- Price
- PBBK $14.11
- NXTC $1.29
- Analyst Decision
- PBBK
- NXTC Strong Buy
- Analyst Count
- PBBK 0
- NXTC 2
- Target Price
- PBBK N/A
- NXTC $4.00
- AVG Volume (30 Days)
- PBBK 1.3K
- NXTC 37.1K
- Earning Date
- PBBK 11-13-2024
- NXTC 11-07-2024
- Dividend Yield
- PBBK N/A
- NXTC N/A
- EPS Growth
- PBBK N/A
- NXTC N/A
- EPS
- PBBK 0.64
- NXTC N/A
- Revenue
- PBBK $11,875,000.00
- NXTC N/A
- Revenue This Year
- PBBK N/A
- NXTC N/A
- Revenue Next Year
- PBBK N/A
- NXTC N/A
- P/E Ratio
- PBBK $22.20
- NXTC N/A
- Revenue Growth
- PBBK N/A
- NXTC N/A
- 52 Week Low
- PBBK $11.71
- NXTC $1.03
- 52 Week High
- PBBK $17.50
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- PBBK 26.10
- NXTC 44.42
- Support Level
- PBBK $14.10
- NXTC $1.28
- Resistance Level
- PBBK $15.12
- NXTC $1.40
- Average True Range (ATR)
- PBBK 0.10
- NXTC 0.09
- MACD
- PBBK -0.06
- NXTC -0.01
- Stochastic Oscillator
- PBBK 0.98
- NXTC 6.06
About PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.